Key market opportunities for GLP-1 analogues include growth in the oral administration segment, expanding presence in Asia-Pacific and emerging markets, and strategic partnerships. Regulatory ...

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare ...

ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, was discovered and developed in-house utilizing Ascletis' Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and ...

HONG KONG, Jan. 20, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that it has selected ASC37 injection, a next-generation, once-monthly, subcutaneously administered ...

Research has shown that people who stop taking GLP-1 drugs, such as Ozempic and Wegovy, typically experience weight regain ...

Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said ...

GALVESTON, TX / ACCESS Newswire / January 12, 2026 / Callan JMB Inc. (NASDAQ:CJMB), a premier provider of vertically ...

Fat jabs haven't just changed the nation's waistlines, they've transformed how and what people eat - and supermarkets haven't ...

Another important component in Lipovive is Banaba Leaf, specifically its active compound Corosolic Acid. This compound has ...

Another bio company, Structure Therapeutics, develops oral obesity treatments. Although it is a latecomer in the obesity treatment sector, it is evaluated as being ahead in developing oral medications ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

As soon as the anaesthetised rat stopped moving, the laboratory technician surgically removed its pancreas. There was no time to waste: the organ could only survive for about an hour outside the body.